Skip directly to search Skip directly to A to Z list Skip directly to page options Skip directly to site content

Volume 16, Number 2—February 2010


Cost-effectiveness of Pharmaceutical-based Pandemic Influenza Mitigation Strategies1

Anthony T. NewallComments to Author , James G. Wood, Noemie Oudin, and C. Raina MacIntyre
Author affiliations: University of New South Wales, Sydney, New South Wales, Australia (A.T. Newall, J.G. Wood, C.R. MacIntyre); National Institute for Applied Sciences, Lyon, France (N. Oudin)

Main Article

Table 2

Base-case economic results per person in the population (healthcare system perspective) of 4 pharmaceutical-based pandemic influenza mitigation strategies*

Strategy no. Net cost Incremental cost LYS Incremental LYS Incremental cost per LYS†
1 65.88
2 82.24 16.36 0.01803 0.01803 908
3 100.65 18.40 0.03501 0.01698 1,084
4 124.00 23.36 0.03814 0.00313 7,458

*LYS, life-year saved. Costs and life-years discounted at 5% annually; all costs calculated in 2005 Australian dollars.
†Rounded to the nearest whole dollar.

Main Article

1This material was compiled before the declaration of pandemic (H1N1) 2009 and concerns stockpiling for a future influenza pandemic.